Abbvie Inc(ABBV-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low244.53
Day High246.96
Open:245.65
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
the globe and mail
A screen displays the share price for drugmaker AbbVie on the floor of the New York Stock Exchange July 18, 2014.
the globe and mail

Wall Street warms to health-care stocks as tech trade faces turbulence

A sector that has long lagged is back ​on the upswing
Motley Fool
Is AbbVie Stock a Buy After Posting Strong Q2 Earnings?
Tipranks
AbbVie Targets Obesity Market With New Phase 2 ABBV-295 Trial
Motley Fool
iShares Global Healthcare ETF vs State Street SPDR Biotech ETF. Which Healthcare-Focused Fund Will Bring You Profits in 2026 and Beyond?
Motley Fool
Vanguard Health Care ETF vs State Street XLV: Which ETF Is the Better Buy for Investors in 2026?
MarketBeat
MarketBeat Week in Review – 08/03 - 08/07
MarketBeat.com
Motley Fool
AbbVie vs. Abbott Laboratories: Which Healthcare Stock Is a Better Buy in 2026?
Motley Fool
Could 1 Tiny Biotech Topple Vertex Pharmaceuticals' Cystic Fibrosis Empire?
StockStory
The 5 Most Interesting Analyst Questions From AbbVie’s Q2 Earnings Call
ABBV
Tipranks
AbbVie prices $9.9B senior notes to fund acquisition
StockStory
3 Cash-Producing Stocks for Long-Term Investors
ABBV
Motley Fool
This Stock Keeps Raising Its Dividend No Matter What the Market Does -- and Wall Street Thinks It's a Buy Right Now
Motley Fool
State Street XLV vs VanEck BBH: Which Healthcare ETF Is the Better Buy in 2026?
Tipranks
Analysts’ Top Healthcare Picks: Oric Pharmaceuticals (ORIC), AbbVie (ABBV)
Tipranks
AbbVie’s RAMpUp Study Targets Real-World Edge in Atopic Dermatitis
Tipranks
AbbVie’s ABBV-706 Lung Cancer Trial: A New Late-Stage Bet in Small Cell Oncology
GlobeNewswire
Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One
Tipranks
Analysts Conflicted on These Healthcare Names: AbbVie (ABBV), HealthStream (HSTM) and Cigna (CI)
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: BrightSpring Health Services, Inc. (BTSG), AbbVie (ABBV) and Novo Nordisk (NVO)
Newswire.ca
UBRELVY® (ubrogepant) Recommended for Reimbursement by Canada's Drug Agency (CDA-AMC) for Acute Migraine Treatment

Profile

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.